Добірка наукової літератури з теми "Komagome (Tokyo)"

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Komagome (Tokyo)".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Статті в журналах з теми "Komagome (Tokyo)"

1

Negishi, Masayoshi. "HIV/AIDS Care at Tokyo Metropolitan Komagome Hospital." Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 14 (1997): S35—S37. http://dx.doi.org/10.1097/00042560-199700002-00007.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Masuda, G., A. Ajisawa, M. Negishi, A. Imamura, Y. Inamura, H. Tachibana, T. Takeuchi, and M. Saito. "Entamoeba histolytica/dispar infections in HIV-positive individuals presented at Tokyo Metropolitan Komagome Hospital, Tokyo." Parasitology International 47 (August 1998): 199. http://dx.doi.org/10.1016/s1383-5769(98)80518-7.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

YASUNO, Akira, Seizo UCHIDA, Hiroshi YAMAGUCHI, Yuichi INOUE, Etsuko YANAGIHA, and Mihoko KUBOTA. "THE CONSTRUCTION PROCESS AND DESIGN OF A REINFORCED CONCRETE APARTMENT BUILDING IN KOMAGOME, TOKYO (1938)." Journal of Architecture and Planning (Transactions of AIJ) 71, no. 600 (2006): 203–9. http://dx.doi.org/10.3130/aija.71.203_2.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Ebara, T., K. Karasawa, K. Maebayashi, H. Kurosaki, H. Ishikawa, T. Kaizu, Y. Tanaka, K. Akagi, and G. Masuda. "Radiation therapy for Kaposi's sarcoma associated with acquired immunodeficiency syndrome: Tokyo Metropolitan Komagome Hospital experience." International Journal of Clinical Oncology 5, no. 6 (December 20, 2000): 395–98. http://dx.doi.org/10.1007/pl00012069.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Suzuki, C., G. Masuda, S. Kano, and M. Suzuki. "Clinical and in vitro efficacy of anti-malarial drugs on 16 Plasmodium falciparum malaria experienced at Tokyo metropolitan Komagome hospital, Tokyo, Japan." Parasitology International 47 (August 1998): 237. http://dx.doi.org/10.1016/s1383-5769(98)80643-0.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Hoshino, Yoshihiko, Gohta Masuda, Masayoshi Negishi, Atsushi Ajisawa, Akifumi Imamura, Kei Hachimori, Naohide Takayama, Tsuyoshi Yamaguchi, and Mikio Kimura. "Clinical and Bacteriological Profiles of Patients with Typhoid Fever Treated during 1975-1998 in the Tokyo Metropolitan Komagome Hospital." Microbiology and Immunology 44, no. 7 (July 2000): 577–83. http://dx.doi.org/10.1111/j.1348-0421.2000.tb02536.x.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Nakajima, Yasushi, Akane Yoshida, and Tsuyoshi Kato. "Report on the Project on the Implementation of Continuity Operations in Disaster-Affected Healthcare Facilities Using Gensai Calendar HDMG and COOP Flow Diagram." Journal of Disaster Research 18, no. 2 (February 1, 2023): 114–23. http://dx.doi.org/10.20965/jdr.2023.p0114.

Повний текст джерела
Анотація:
Based on the lessons learned from past disasters, the Japanese Ministry of Health, Labour and Welfare has notified the establishment of disaster base hospitals and ensured medical care continuity based on business continuity plan (BCP). Following these, we created a disaster management training program with 45 items, the Disaster Mitigation (Gensai) Calendar for Healthcare Disaster Management Guide (HDMG)* (“Gensai Calendar”) in 2018. Thereafter, a three-year multicenter project was launched at the Tokyo Metropolitan Hospital Organization to introduce the “Gensai Calendar” and assess its merits as a self-learning material through tests based on it. The project also aimed at establishing a common operating procedure (COOP) for medical continuity at affected healthcare facilities using annual comprehensive disaster drills. The numbers of participants and hospitals recruited for the test over the three-year period were 4,281 in six hospitals, 6,179 in ten hospitals, and 6,216 in seven hospitals. The total of 55 questions were asked in the e-learning format in the first and second years, and 11 in the third year. Questions with less than 70% correct rate were same for three years. Through the drills, a COOP flow diagram was constructed based on the initial responses in the wards. Furthermore, the crisis management system of each hospital was unified, and each BCP was revised into a standard document along the “COOP Flow Diagram.” A COOP system combining the “Gensai Calendar” learnings, annual “COOP Flow Diagram” drill, and standard documentation can be a viable system for medical continuity. This system could also be versatile and introduced to many healthcare facilities. * This is also the abbreviation for the Hiroo Disaster Management Group, which has a double meaning. The group consists of disaster prevention staff from the Tokyo Metropolitan Hiroo Hospital, Komagome Hospital, and Bokutoh Hospital, and is responsible for planning and managing disaster mitigation measures.
Стилі APA, Harvard, Vancouver, ISO та ін.
8

KAMINUMA, Takuya, Katsuyuki KARASAWA, Nahoko HANYU, Ta-Chen CHANG, Gencho KUGA, Naoko OKANO, Nobuteru KUBO, et al. "Acute Adverse Effects of Radiation Therapy on HIV-positive Patients in Japan: Study of 31 Cases at Tokyo Metropolitan Komagome Hospital." Journal of Radiation Research 51, no. 6 (2010): 749–53. http://dx.doi.org/10.1269/jrr.10090.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Kobayashi, Takeshi, Takuya Yamashita, Miwa Sakai, Yoshiki Okuyama, Kazuteru Ohashi, Hideki Akiyama, Kiyoshi Hiruma, and Hisashi Sakamaki. "Single-Institute Analysis of Allogeneic Stem Cell Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia." Blood 106, no. 11 (November 16, 2005): 5445. http://dx.doi.org/10.1182/blood.v106.11.5445.5445.

Повний текст джерела
Анотація:
Abstract Purpose We report the outcomes of allogeneic stem cell transplantation (SCT) for the patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) in a single center. Patients and Methods Between August 1993 and March 2005, 36 patients with Ph+ALL received SCT at Tokyo Metropolitan Komagome Hospital. The median age was 41 years (range; 17 to 60 years). All patients received myeloablative conditioning regimen (cytosine arabinoside, cyclophosphamide and fractionated 12Gy total-body irradiation). Stem cell source of SCT was 14 related donors (bone marrow [n=9] and peripheral blood stem cell [n=5]) and 22 unrelated donors (bone marrow [n=13] and cord blood [n=9]). Results Seventeen (47%) of 36 patients are alive at a median of 2.16 years (range; 1.0 to 3.3 years) after transplantation. Three years overall survival (OS) and disease free survival (DFS) for all patients are 42.3% and 35.4%, respectively. Three years OS and DFS are 55.4% and 46.4% for the 24 patients in complete remission (CR) at transplantation, while 36.4% (p<0.001) and 16.7% (p<0.01) for the 12 patients in non-CR, respectively. Stem cell source and patients age do not affect the outcomes. The higher white blood cell counts at diagnosis are associated with poor OS (p=0.003). The median duration from diagnosis to SCT is 7 months (range; 3 to 29 months). Three years OS of the patients who received SCT within 7 months from diagnosis is better than that of the others (59.3% vs. 31.1%, p=0.019). Conclusion This analysis suggests that shorter duration between diagnosis and transplantation improve the clinical outcomes of SCT for Ph+ALL, especially performed in CR.
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Takagi, Maki, Misato Takao, Nozomi Funatsu, Soichiro Natsume, Daisuke Nakano, Kazushige Kawai, and Tatsuro Yamaguchi. "Clinicopathologic characteristics of patients with early-onset colorectal cancer." Journal of Clinical Oncology 42, no. 3_suppl (January 20, 2024): 74. http://dx.doi.org/10.1200/jco.2024.42.3_suppl.74.

Повний текст джерела
Анотація:
74 Background: Although the incidence of colorectal cancer has been declining in the United States in recent years, the incidence of young patients under 50 years of age has been reported to be increasing by several percent per year. Various studies have been conducted to characterize early-onset colorectal cancer (EO-CRC); however, it has been unclear whether it is a different entity from late-onset colorectal cancer (LO-CRC). In this study, we evaluated the clinicopathologic characteristics of EO-CRC in Japan. Methods: This study included 1,336 patients who underwent surgical resection for colorectal cancer at Tokyo Metropolitan Komagome Hospital from January 2015 to December 2019. We performed genetic testing for patients with suspected Lynch syndrome after providing genetic counseling and obtaining informed consent. The study protocol was approved by the Institutional Review Board. Results: Of the 1,336 colorectal cancer patients, 117 (8.9%) had EO-CRC with a median age at the diagnosis of 44 (17–49) years. Tumors were located at right-sided colon in 23 patients and left-sided colorectum in 92 patients with EO-CRC, respectively. The clinical stage of the tumor was I in 19, II in 23, III in 50, and IV in 23 patients with EO-CRC, respectively. Histologically, differentiated type, undifferentiated type, and mucinous carcinoma were 106, 5, and 3 patients, respectively. KRAS mutation was detected in 25.0% and BRAF V600E was detected in 4.3% of patients with EO-CRC. In the microsatellite status, MSI-High was detected in 6 (5.1%) patients with EO-CRC, of whom 3 (2.6%) were diagnosed with Lynch syndrome by genetic testing. Causative genes were MLH1 in 2 patients and MSH2 in one patient. In hereditary tumors, 2 patients with familial adenomatous polyposis were included in addition to Lynch syndrome. On the other hand, 1,219 (91.2%) had LO-CRC with 34.5% of KRAS mutation and 6.4% of BRAFV600E. MSI-High was detected in 69(5.7%) patients with LO-CRC,of whom 5 (0.4%) were diagnosed with Lynch syndrome. Lynch syndrome was significantly more common in EO-CRC (p=0.026). Conclusions: The alterations of KRAS and BRAF tended to be more frequent in EO-CRC. The frequency of hereditary CRC was more frequent in EO-CRC than in LO-CRC.
Стилі APA, Harvard, Vancouver, ISO та ін.
Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!

До бібліографії